Novel evidence for retinoic acid-induced G (Rig-G) as a tumor suppressor by activating p53 signaling pathway in lung cancer.


Journal

FASEB journal : official publication of the Federation of American Societies for Experimental Biology
ISSN: 1530-6860
Titre abrégé: FASEB J
Pays: United States
ID NLM: 8804484

Informations de publication

Date de publication:
09 2020
Historique:
received: 22 01 2020
revised: 20 05 2020
accepted: 23 06 2020
pubmed: 3 8 2020
medline: 11 3 2021
entrez: 3 8 2020
Statut: ppublish

Résumé

Lung cancer is one of most common malignancies worldwide. We have previously identified retinoic acid-induced gene G (Rig-G) as a tumor suppressor in not only acute promyelocytic leukemia, but also in other solid tumors. However, the clinical significance of Rig-G and the underlying mechanism(s) for its biological function in lung cancer remain largely unexplored. Herein, we first compared the expression of Rig-G between lung cancer (n = 138) and normal tissues (n = 23), from public-available data sets and our patient cohort. We further analyzed the correlation of Rig-G expression with key clinico-pathological features and survival outcomes in a multi-site clinical cohort of 300 lung cancer patients. Functional studies for Rig-G were performed in cell lines, and an animal model to support clinical findings. We found that Rig-G was frequently downregulated in lung cancer tissues and cell lines, and correlated with poor prognosis in lung cancer patients. Overexpression of Rig-G led to significantly reduced cell growth and suppressed migration in A549 and NCI-H1944 cells, accompanied by reduced epithelial-mesenchymal transition. Likewise, restoration of Rig-G in Lewis lung carcinoma cells permitted development of fewer cancer metastases versus controls in an animal model. Gene expression profiling results identified p53 pathway as a key downstream target of Rig-G, and p53 inhibition by pifithrin-α caused abrogation of tumor-suppressive effects of Rig-G in lung cancer. In conclusion, we, for the first time, have identified Rig-G as a novel and important tumor suppressor, which may serve as a potential therapeutic target for restoring p53 expression in lung cancer patients.

Identifiants

pubmed: 32741018
doi: 10.1096/fj.201903220R
pmc: PMC7725982
mid: NIHMS1620508
doi:

Substances chimiques

IFIT3 protein, human 0
Intracellular Signaling Peptides and Proteins 0
TP53 protein, human 0
Tumor Suppressor Protein p53 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

11900-11912

Subventions

Organisme : NCI NIH HHS
ID : R01 CA184792
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA187956
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA181572
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA072851
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA202797
Pays : United States

Informations de copyright

© 2020 Federation of American Societies for Experimental Biology.

Références

EMBO Rep. 2018 Jan 2;19(2):305-319
pubmed: 29295817
Cancer Treat Rev. 2019 Jan;72:15-27
pubmed: 30445271
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13790-5
pubmed: 11707567
Mol Biol Cell. 2011 Dec;22(24):4750-64
pubmed: 22031288
Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7406-11
pubmed: 9207104
Neoplasia. 2009 Jan;11(1):22-31, 6p following 31
pubmed: 19107228
Cancer Res. 2018 Jan 15;78(2):359-371
pubmed: 29187402
Oncogene. 2008 Sep 18;27(42):5543-53
pubmed: 18504427
Mol Cancer. 2018 Feb 19;17(1):38
pubmed: 29455650
Mol Cancer Res. 2014 Jan;12(1):3-13
pubmed: 24442106
Genomics. 1998 Dec 1;54(2):267-77
pubmed: 9828129
J Thorac Oncol. 2009 Jun;4(6):679-83
pubmed: 19461401
Cancer Res. 2004 Apr 1;64(7):2439-48
pubmed: 15059897
Cancer Res. 2009 Apr 15;69(8):3673-80
pubmed: 19351818
Biomed Res Int. 2015;2015:621324
pubmed: 26064932
Mutat Res. 2017 Jul;773:1-13
pubmed: 28927521
Biochem Biophys Res Commun. 2013 Mar 15;432(3):425-30
pubmed: 23415865
Cancer Discov. 2014 Apr;4(4):405-14
pubmed: 24658082
Transl Lung Cancer Res. 2018 Feb;7(1):4-20
pubmed: 29535909
J Clin Med. 2016 Jan 27;5(2):
pubmed: 26828526
Oncotarget. 2016 Oct 4;7(40):66032-66050
pubmed: 27602766
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16448-53
pubmed: 17050680
Breast Cancer. 2018 Sep;25(5):529-538
pubmed: 29516369
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593

Auteurs

Junjun Sun (J)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Xuan Wang (X)

Department of Pharmacy, Putuo People's Hospital, Shanghai, China.

Wenfang Liu (W)

Department of General Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Ping Ji (P)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Anquan Shang (A)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Junlu Wu (J)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Hao Zhou (H)

Department of General Surgery, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Wenqiang Quan (W)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Yiwen Yao (Y)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Yibao Yang (Y)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

ChenZheng Gu (C)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Zujun Sun (Z)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Ajay Goel (A)

Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute of City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Wenhao Weng (W)

Department of Clinical Laboratory, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.
Institute of Gastrointestinal Surgery and Translational Medicine, Yangpu Hospital, Tongji University School of Medicine, Shanghai, China.

Dong Li (D)

Department of Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH